



Classification of Focus
● Active foci

I. Epidemiological profile

Population (UN)	2016	%
Number of active foci	27	
Number of people living within active foci	30,900	8
Malaria-free (0 cases)	336,000	92
Total	367,000	

Parasites and vectors	
Plasmodium species:	P. falciparum (0%), P. vivax (100%)
Major anopheles species:	<i>An. albimanus, An. darlingi</i>
Reported confirmed cases (health facility):	4
Confirmed cases at community level:	-
Reported deaths:	0

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	2009
	ITNs/ LLINs distributed to all age groups	Yes	2010
IRS	IRS is recommended	Yes	-
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	-
Treatment	ACT is free of charge for all ages in public sector	Yes	2010
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for P. falciparum	Yes	-
	Primaquine is used for radical treatment of P. vivax	Yes	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	No	-
Surveillance	System for monitoring adverse reactions to antimalarials exists	No	-
	ACD for case investigation (reactive)	Yes	-
	ACD of febrile cases at community level (pro-active)	Yes	-
	Mass screening is undertaken	Yes	-
	Uncomplicated P. falciparum cases routinely admitted	No	-
	Uncomplicated P. vivax cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	-
Case reporting from private sector is mandatory	Yes	-	

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of P. falciparum	CQ+PQ(1d)	-
Treatment failure of P. falciparum	QN	-
Treatment of severe malaria	QN	-
Treatment of P. vivax	CQ+PQ(14d)	-
Dosage of Primaquine for radical treatment of P. vivax		0.25 mg/Kg (14 days)
Type of RDT used		-

Therapeutic efficacy tests (clinical and parasitological failure, %)


Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
----------	---------	-----	--------	-----	-----------	----------------	---------

Insecticide resistance tests (mosquito mortality, %)


Insecticide class	Years	Min	Mean	Max	No. of sites	Species
-------------------	-------	-----	------	-----	--------------	---------

III. Financing

Sources of financing




Government expenditure by intervention in 2016




IV. Coverage


Coverage of ITN and IRS




Cases tested



Cases treated




Cases tracked




V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



Notes:
Reported confirmed cases and reported deaths are indigenous only